Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. 

Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality.

To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape.

Defining the Endovascular Procedure Landscape

Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, peripheral, neurovascular, and venous procedures. Collectively, these categories represent a substantial volume of global clinical activity.

Based on data shared in Microbot’s past presentations, there are approximately 6 million applicable procedures annually in the U.S. and close to 15 million worldwide that could theoretically benefit from robotic assistance.

Breaking that total down by segment highlights where growth and opportunity are most concentrated:

Viewed together, these figures help explain why many companies in this space are prioritizing peripheral and neurovascular indications as initial entry points.

Why Peripheral and Neurovascular Matter in Endovascular Robotics

Two factors shape where robotic systems are most likely to gain traction early: disease prevalence and procedural complexity.

From a prevalence standpoint, peripheral and venous disease affect a massive patient population. Estimates suggest 8 to 10 million adults in the U.S. live with peripheral artery disease, while chronic venous disease impacts more than 25 million adults. When ranked by prevalence in the U.S., the burden of disease falls in this order: peripheral, coronary, neurovascular.

Complexity tells a different but complementary story. Neurovascular interventions are generally the most technically demanding, followed by peripheral procedures, with coronary work often considered the most standardized. In endovascular care, complexity matters because surgical robotics tend to offer the most value when precision, navigation, and operator fatigue become limiting factors.

By reducing technical burden and improving control, robotic assistance has the potential to expand access to treatment while improving consistency across operators.

The Competitive Landscape Today

Endovascular robotics is not a brand-new concept. The first commercially available systems entered the market more than a decade ago.

Corindus, later acquired by Siemens Healthineers, was the earliest player to receive FDA approval with its CorPath system. In 2023, Siemens halted commercial efforts for CorPath, and the program remained quiet until the company recently announced a partnership with Stryker to jointly pursue a neurovascular-focused robotic platform.

Other companies with commercially available or regionally approved systems include:

• Stereotaxis, whose Genesis magnetic navigation platform is FDA-cleared for cardiac ablation and other endovascular applications
• Robocath, which has received CE mark approval for its R-One PCI system
• MicroPort and Robocath, which have collaborated to introduce the Cathbot system in China

Several emerging companies are also worth watching:

• XCath, developing the EVR neurovascular robotic system
• NAVIGANTIS, advancing the VASCO platform for neurovascular procedures
• Nanoflex Robotics, focused on flexible endovascular robotics
• Sentante, working on a fully-robotic teleoperated system for endovascular interventions

Notably, there is no dominant Intuitive-style incumbent in this category today. That absence lowers the barriers for new entrants and creates space for differentiated system designs to gain clinical and commercial traction.

Microbot Medical’s Differentiated Approach

Microbot’s LIBERTY system stands apart from most robotic platforms currently in development. Rather than relying on a capital-intensive robot installed in the operating room, LIBERTY is a single-use, cassette-style system that is remotely operated.

LIBERTY is also the only FDA-cleared, single-use, remotely operated endovascular robotic system designed specifically for peripheral procedures. The system aims to improve navigation precision while reducing radiation exposure and physical strain for clinicians.

The recent adoption at Emory University Hospital represents more than a symbolic first use. Microbot is collaborating with Emory to establish an Endovascular Robotics Program within interventional radiology.

Looking Ahead

Microbot Medical’s progress offers a snapshot of the endovascular robotics market, which is still early but increasingly competitive. As robotic adoption expands across endovascular care, platforms that lower cost barriers while addressing real clinical pain points are likely to gain attention.

With a full commercial launch planned for 2026 and early clinical use now underway, Microbot’s trajectory will be closely watched.